Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1Approved for marketing 1

Sponsor Class

OTHER 2

Study Type

Interventional 1Expanded_access 1

Sponsor

Cancer Type

Sarcoma 2Other hematologic neoplasm 2Lymphoid 2

Conditions

Osteosarcoma 6Renal Insufficiency 2Lymphoma 2Leukemia 2Water Intoxication 1Neoplasms 1Mucositis 1Hematologic Neoplasms 1Drug-Related Side Effects and Adverse Reactions 1Acute Kidney Injury 1

Interventions

Cyclophosphamide 48fludarabine phosphate 28Filgrastim 27Radiotherapy 26Antilymphocyte Serum 26Busulfan 24Cyclosporine 23Peripheral Blood Stem Cell Transplantation 19Mycophenolic Acid 18Cord Blood Stem Cell Transplantation 17Methylprednisolone 16Methotrexate 16Melphalan 15Etoposide 15Tacrolimus 12Whole-Body Irradiation 11Cytarabine 9Thiotepa 6Vincristine 5Psychiatric Rehabilitation 5sargramostim 4aldesleukin 4Sirolimus 4Leucovorin 4Granulocyte Colony-Stimulating Factor 4fludarabine 3Prednisone 3Early Intervention, Educational 3Daunorubicin 3glucarpidase 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Leukemia × glucarpidase × Sarcoma × Clear all
NCT00634504 2022-06-06

LVPK

BTG International Inc.

Phase 1 Completed
20 enrolled 9 charts
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Osteosarcoma, Renal Insufficiency

NCT00481559 2014-01-17

Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity

BTG International Inc.

Approved for marketing
LymphoidOther hematologic neoplasmSarcoma

Leukemia, Lymphoma, Neoplasms, Osteosarcoma, Renal Insufficiency

Data powered by HemOnc (CC BY 4.0) Colophon âš¡